Literature DB >> 18626273

Physician Withdrawal Checklist (PWC-20).

Karl Rickels1, Felipe Garcia-Espana, Laura A Mandos, George W Case.   

Abstract

Anxiety disorders are the most common mental illnesses in the United States. Despite having a number of medication options readily available, benzodiazepines (BZs) and antidepressants have achieved remission rates of only 35% after 8 weeks of acute treatment. In the development of new anxiolytics, particularly those that affect the gamma-aminobutyric acid system, it is essential to assess the new compound's potential to cause discontinuation symptoms after stopping the medication as part of both short- and long-term treatment. This report describes the development of the 20-item Penn Physician Withdrawal Checklist (PWC), a smaller version of the original 35-item PWC, and examines its validity, internal consistency, test-retest and interrater reliability, and factor structure. The PWC scores, assessed at the peak of withdrawal severity, were selected from 143 of our patients for an orthogonal factor analysis. Our results suggest that the Penn Physician Withdrawal Checklist is a simple and accurate method to assess anxiolytic discontinuation symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626273     DOI: 10.1097/JCP.0b013e31817efbac

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

1.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Madhukar H Trivedi; Adam Janik; Honglan Li; Yun Zhang; Xiang Li; Rosanne Lane; Pilar Lim; Anna R Duca; David Hough; Michael E Thase; John Zajecka; Andrew Winokur; Ilona Divacka; Andrea Fagiolini; Wieslaw J Cubala; István Bitter; Pierre Blier; Richard C Shelton; Patricio Molero; Husseini Manji; Wayne C Drevets; Jaskaran B Singh
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

2.  Effects of pregabalin in patients with hypnotic-dependent insomnia.

Authors:  Youg Won Cho; Mei Ling Song
Journal:  J Clin Sleep Med       Date:  2014-05-15       Impact factor: 4.062

3.  The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Authors:  George Haig; Deli Wang; Ahmed A Othman; Jun Zhao
Journal:  Neuropsychopharmacology       Date:  2016-06-20       Impact factor: 7.853

4.  Anxiolytic-like effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in experimental mouse models of anxiety.

Authors:  Shvetank Bhatt; Radhakrishnan Mahesh; Thangaraj Devadoss; Ankur Kumar Jindal
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

5.  Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.

Authors:  Kenneth S Koblan; Seth C Hopkins; Kaushik Sarma; Fengbin Jin; Robert Goldman; Scott H Kollins; Antony Loebel
Journal:  Neuropsychopharmacology       Date:  2015-05-07       Impact factor: 7.853

6.  Levo-Tetrahydroberberrubine Produces Anxiolytic-Like Effects in Mice through the 5-HT1A Receptor.

Authors:  Guiyun Mi; Shuai Liu; Jian Zhang; Huichun Liang; Yunyun Gao; Nuomin Li; Boyang Yu; Hongju Yang; Zheng Yang
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

7.  A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects.

Authors:  Klaus Schaffler; Ashraf Yassen; Peter Reeh; Paul Passier
Journal:  Pain Med       Date:  2018-06-01       Impact factor: 3.750

8.  Anti-anxiety effect of a novel 5-HT₃ receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice.

Authors:  Yeshwant Vijay Kurhe; Mahesh Radhakrishnan; Devadoss Thangaraj; Deepali Gupta
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

9.  A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia.

Authors:  Virginia L Stauffer; Simin K Baygani; Bruce J Kinon; Judith O Krikke-Workel
Journal:  J Clin Psychopharmacol       Date:  2014-10       Impact factor: 3.153

10.  Involvement of 5-HT1A Receptors in the Anxiolytic-Like Effects of Quercitrin and Evidence of the Involvement of the Monoaminergic System.

Authors:  Jian Li; Qian-Tong Liu; Yi Chen; Jie Liu; Jin-Li Shi; Yong Liu; Jian-You Guo
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.